Search for
Knee tissue - Large Biopsy 3-6 cm
Biopsy
Report in 288Hrs
At Home
No Fasting Required
Details
Joint tissue biopsy.
₹666₹951
30% OFF
Knee Tissue - Large Biopsy 3-6 cm
- Why is it done?
- To diagnose musculoskeletal pathology affecting the knee joint, including tumors (benign and malignant), cysts, cartilage disorders, and soft tissue abnormalities
- To obtain sufficient tissue samples for comprehensive histopathological examination and specialized testing (immunohistochemistry, molecular analysis, electron microscopy)
- To differentiate between different types of knee lesions when imaging findings are inconclusive or suggest malignancy
- When needle biopsies have been non-diagnostic or yield insufficient material for accurate diagnosis
- To assess for infectious, inflammatory, or degenerative conditions of the knee when clinical and imaging findings warrant tissue confirmation
- Typically performed when imaging studies (MRI, ultrasound, CT) have identified an abnormality requiring definitive diagnosis or when clinical suspicion warrants tissue-level evaluation
- Normal Range
- Normal Result: Absence of malignant cells, absence of infectious organisms, normal or expected histological architecture for the specific tissue sampled (cartilage, synovium, bone, fibrous tissue)
- Benign Findings: Non-neoplastic lesions such as ganglion cysts, synovial inflammation, degenerative changes, hemangiomas, lipomas, or fibromas
- Specimen Adequacy: Biopsy tissue measuring 3-6 cm provides adequate material for definitive diagnosis; sufficient cellular material for microscopic examination and special stains
- Negative for Malignancy: No evidence of primary malignant neoplasm (sarcoma, lymphoma) or metastatic disease; normal mitotic activity and cellular morphology
- Interpretation
- Malignant Findings: Presence of neoplastic cells indicating primary bone or soft tissue sarcoma (osteosarcoma, Ewing sarcoma, chondrosarcoma, synovial sarcoma, liposarcoma); lymphoproliferative disorders; or metastatic malignancy. Results are typically classified according to tumor grade and type with specific recommendations for staging and treatment.
- Infectious Processes: Identification of bacterial, fungal, mycobacterial, or viral organisms; inflammatory infiltration consistent with infection; culture and sensitivity results guide antibiotic or antimicrobial therapy
- Inflammatory Conditions: Evidence of rheumatoid arthritis, seronegative spondyloarthropathies, granulomatous disease, lupus, or other autoimmune processes affecting synovium and joint tissues
- Degenerative Changes: Cartilage degeneration, osteophyte formation, synovial hypertrophy, or fibrosis consistent with osteoarthritis or other joint degenerative disorders
- Benign Neoplasms: Histologic confirmation of benign tumors such as osteochondromas, enchondromas, giant cell tumors of tendon sheath, fibromas, hemangiomas, or lipomas; generally does not require aggressive treatment
- Factors Affecting Interpretation: Prior treatment (chemotherapy, radiation), specimen fixation and processing, tissue sampling location, presence of crush artifact or necrosis, performance of special stains and immunohistochemistry, and correlation with clinical history and imaging findings
- Specimen Characteristics: Large biopsy (3-6 cm) allows for comprehensive evaluation of lesion architecture, margin assessment, and heterogeneous tissue composition, improving diagnostic accuracy and reducing sampling error compared to smaller needle biopsies
- Associated Organs
- Primary Organ System: Musculoskeletal system, including bone, cartilage, synovium, ligaments, tendons, and surrounding soft tissues of the knee joint
- Primary Malignancies: Osteosarcoma (most common in adolescents around the knee), Ewing sarcoma, chondrosarcoma, synovial sarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, angiosarcoma
- Hematologic Malignancies: Lymphoma (primary bone lymphoma, Hodgkin lymphoma), myeloma involving knee structures
- Benign Tumors: Osteochondroma, osteoma, giant cell tumor of bone, giant cell tumor of tendon sheath, ganglion cyst, hemangioma, lipoma, fibroma, meniscal cyst
- Infectious Diseases: Bacterial septic arthritis, osteomyelitis (Staphylococcus, Streptococcus, Gram-negative organisms), tuberculosis, fungal infections (histoplasmosis, coccidioidomycosis), atypical mycobacterial infections
- Inflammatory and Autoimmune Conditions: Rheumatoid arthritis, seronegative spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, gout, pseudogout, pigmented villonodular synovitis (PVNS)
- Potential Complications from Abnormal Results: Malignant tumors may metastasize if untreated; infections can progress to sepsis or bone destruction; inflammatory conditions may lead to progressive joint destruction and disability; biopsy itself carries minor risks including bleeding, infection, nerve injury, and temporary pain
- Follow-up Tests
- If Malignancy Diagnosed: Complete staging studies (chest CT, abdomen/pelvis imaging, bone scan or PET-CT), MRI for surgical planning, tumor markers as appropriate, molecular testing and cytogenetics for prognostic classification (MDM2/CDK4 amplification, TP53, FUS-DDIT3 fusion), sentinel lymph node biopsy or regional lymph node imaging
- If Infection Identified: Culture and sensitivity testing, repeat imaging to assess treatment response, blood cultures if bacteremia suspected, antibiotic susceptibility testing, follow-up imaging (MRI, ultrasound) to confirm resolution
- If Inflammatory/Autoimmune Condition: Serology (rheumatoid factor, anti-CCP, ANA, ESR, CRP), HLA typing, imaging surveillance with MRI or ultrasound, rheumatology consultation, therapy initiation and monitoring with follow-up clinical assessments
- If Benign Lesion Confirmed: Surveillance imaging at determined intervals (typically 6-12 months initially), clinical follow-up for symptom assessment, surgical resection if symptomatic or showing growth, repeat biopsy only if imaging characteristics change or clinical suspicion for malignancy increases
- Specialty Consultations: Orthopedic oncology consultation for malignant tumors, infectious disease consultation for infections, rheumatology for inflammatory conditions, pathology consultation for complex cases requiring expert opinion or second review
- Imaging Surveillance: Serial MRI for treatment response monitoring, follow-up radiographs to assess local recurrence, ultrasound for soft tissue assessment, PET-CT for detection of metastatic disease during treatment and follow-up
- Fasting Required?
- Fasting Requirement: No fasting required for the tissue biopsy itself. However, fasting may be required if the procedure will be performed under general anesthesia or conscious sedation, depending on institutional protocols and anesthesia guidelines.
- Pre-Procedure Preparation: If sedation/anesthesia planned: NPO (nothing by mouth) for 6-8 hours prior; if local anesthesia only: no fasting required; informed consent documentation; baseline vital signs and laboratory work if needed (CBC, PT/INR, PTT, type and cross-match if extensive bleeding possible)
- Medications: Discontinue anticoagulants (warfarin, apixaban, rivaroxaban) 3-5 days prior if possible; hold antiplatelet agents (aspirin, clopidogrel) 5-7 days prior; NSAIDs held 3-5 days before; coordinate with prescribing physician regarding timing of medication resumption; prophylactic antibiotics may be given perioperatively in certain cases
- Additional Requirements: Remove jewelry, watches, and metal objects; empty bladder before procedure; wear comfortable, loose-fitting clothing; arrange transportation if sedation used; report any active infections or recent fevers to physician; bring imaging studies (MRI, CT, ultrasound) showing lesion location; discuss allergies (especially local anesthetics) with clinical team; confirm absence of pregnancy if applicable
- Post-Procedure Instructions: Ice application and elevation for first 24-48 hours; pain management with acetaminophen or prescribed analgesics; avoid strenuous activity for 1-2 weeks; observe surgical site for signs of infection or excessive bleeding; keep dressing dry and intact as instructed; follow activity restrictions based on biopsy technique and location; follow-up appointment typically scheduled 2-4 weeks after procedure
How our test process works!
